Sepsis

Nangibotide Gets Fast Track Status for Treatment of Septic Shock

The Food and Drug Administration (FDA) has granted Fast Track designation to nangibotide (LR12; Inotrem S.A.) for the treatment of septic shock. Nangibotide, a TREM-1 (triggering receptor expressed on myeloid cells-1) inhibitor, is a chemically synthesized peptide that acts as a decoy receptor interfering with the binding of TREM-1 and its ligand. Based on preclinical…